Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 7/20 | 0.68 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.68 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.68 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.68 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.68 |
| ▸ | CFTR | P13569 | 2/20 | 0.64 |
| ▸ | ADORA2B | P29275 | 9/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.60 |
| ▸ | CHIT1 | Q13231 | 1/20 | 0.60 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.60 |
| ▸ | PDE2A | O00408 | 2/20 | 0.54 |
| ▸ | PDE1A | P54750 | 2/20 | 0.54 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.54 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.54 |
| ▸ | PDE5A | O76074 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6355083 | 1.00 | PDE4A (0.68) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL6349412 | 1.00 | PDE4A (0.68) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL6773798 | 0.99 | PDE4A (0.67) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL9430818 | 0.96 | PDE4A (0.70) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL9430480 | 0.92 | CFTR (0.71) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL6773562 | 0.88 | PDE4A (0.65) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL27776316 | 0.87 | PDE4A (0.71) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL6773962 | 0.87 | PDE4A (0.64) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL27604766 | 0.87 | PDE4A (0.64) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL27604767 | 0.87 | PDE4A (0.64) | PDE4APDE4BPDE4CPDE4DADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130122050-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | DIAKINE THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20110052625-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | DIAKINE THERAPEUTICS, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| EP-1171442-B1 | XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALLING INHIBITORS | CELL THERAPEUTICS INC (US) | 2005-12-07 | — | — | EP | disclosed |
| US-6878715-B1 | Therapeutic compounds for inhibiting interleukin-12 signals and method for using same | CELL THERAPEUTICS, INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-20050049262-A1 | Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same | CELL THERAPEUTICS, INC. (US) | 2005-03-03 | — | — | US | disclosed |
| EP-1171442-A1 | XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALLING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000061583-A1 | XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130122050-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | IAPP, LITAF, IGF2BP1 | PDE4A 1788/4885PDE4B 2888/4885PDE4C 2497/4885 |
| US-20110052625-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | IAPP, LITAF, IGF2BP1 | PDE4A 1352/4885PDE4B 2245/4885PDE4C 1995/4885 |
| US-20050049262-A1 | Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same | IL2, CCR10, CCR1 | PDE4A 4128/4885PDE4B 4566/4885PDE4C 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.